Evidence map›Paper›PMID 42489835›Full record

ReviewBiotechnology journal2026

Synthetic Biology of Sclareol: From the Plant Biosynthetic Pathway to Engineered Microbial and Photosynthetic Chassis.

Yichen Li, Lidan Ye, Hongwei Yu

Abstract readReview
In one paragraph

Review in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yichen LiKey Laboratory of Biomass Chemical Engineering (Education Ministry), College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0009-0003-9062-2275
Lidan YeKey Laboratory of Biomass Chemical Engineering (Education Ministry), College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0002-6248-8457
Hongwei YuKey Laboratory of Biomass Chemical Engineering (Education Ministry), College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0002-9144-4496

Funding

Fundamental Research Funds for the Central Universities 226-2025-00043National Natural Science Foundation of China 22478340National Natural Science Foundation of China 32471481
6 · The paper itself

Abstract

Sclareol is a highly valued bicyclic diterpene widely used as a precursor for the fragrance ambroxide and has also attracted interest as a bioactive natural product. Traditional production relies heavily on plant extraction, primarily from Salvia sclarea, an approach constrained by environmental variability, long cultivation cycles, and costly downstream purification. To overcome these supply bottlenecks, synthetic biology-enabled biomanufacturing has emerged as a sustainable and scalable alternative. Recent advances in synthetic biology and metabolic engineering have enabled the elucidation and reconstruction of the sclareol biosynthetic pathway in heterologous hosts. This review summarizes current knowledge of sclareol biosynthesis, highlights representative engineering strategies for its production in microbial cell factories, while briefly introducing emerging photosynthetic and plant-based platforms as complementary green production systems. Finally, we outline the current challenges and future perspectives for the industrial biomanufacturing of sclareol and other high-value terpenoids.

Indexed as

DiterpenesMetabolic EngineeringPlantsSynthetic BiologyBiosynthetic PathwaysPhotosynthesisSalviaDiterpenessclareolbiosynthesiscell factorymetabolic engineeringsclareolsynthetic biology

Identifiers

PMID42489835
PMCPMC13394516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.